{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "32484630",
  "DateCompleted": {
    "Year": "2021",
    "Month": "03",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "03",
    "Day": "15"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1545-9616",
      "JournalIssue": {
        "Volume": "19",
        "Issue": "5",
        "PubDate": {
          "Year": "2020",
          "Month": "May",
          "Day": "01"
        }
      },
      "Title": "Journal of drugs in dermatology : JDD",
      "ISOAbbreviation": "J Drugs Dermatol"
    },
    "ArticleTitle": "A Randomized Trial of Broad Area ALA-PDT for Field Cancerization Mitigation in High-Risk Patients.",
    "Pagination": {
      "StartPage": "452",
      "EndPage": "458",
      "MedlinePgn": "452-458"
    },
    "Abstract": {
      "AbstractText": [
        "The relationship between actinic keratoses (AKs) and nonmelanoma skin cancers (NMSCs) is well established. Patients with field cancerization are at high risk of developing new lesions. A treatment to interrupt new lesion formation or progression is required.",
        "To evaluate occurrence of AKs in high-risk patients after field aminolevulinic acid&ndash;photodynamic therapy (ALA&ndash;PDT).",
        "In this randomized, parallel-group, evaluator-blinded, 52-week study, patients with 4&ndash;15 facial AKs (N = 166) were random-ized (ALA 2x vs ALA 3x vs vehicle [VEH]-pooled [VEH 2x+VEH 3x], 1:1:1) to receive 2 or 3 PDT treatments (1-hour incubation) following cryotherapy at screening.",
        "More ALA-treated patients than VEH-treated patients had no AKs at week 52 (ALA 2x, 36.0%, P=0.0102; ALA 3x, 37.5%, P=0.0089; VEH, 18.9%). Week 52 lesion recurrence rates were 7.7% (P=0.0004) and 6.1% (P&lt;0.0001) for ALA 2x and ALA 3x, respec-tively, versus 15.5% for VEH. Therapy was well tolerated; no patient requested early termination of light treatment. ALA 3x reduced NMSC development versus VEH (5 vs 12 lesions, P=0.0014).",
        "2 or 3 ALA&ndash;PDT treatments with 1-hour incubation can significantly reduce occurrence of AKs after 1 year in patients at high risk of NMSC versus VEH&ndash;PDT (NCT02239679). J Drugs Dermatol. 2020;19(5):452-458. doi:10.36849/JDD.2020.4930."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Piacquadio",
        "ForeName": "Daniel",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Houlihan",
        "ForeName": "Anna",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ferdon",
        "ForeName": "Mary Beth",
        "Initials": "MB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Berg",
        "ForeName": "James E",
        "Initials": "JE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Marcus",
        "ForeName": "Stuart L",
        "Initials": "SL"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial, Phase II",
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "J Drugs Dermatol",
    "NlmUniqueID": "101160020",
    "ISSNLinking": "1545-9616"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Photosensitizing Agents"
    },
    {
      "RegistryNumber": "88755TAZ87",
      "NameOfSubstance": "Aminolevulinic Acid"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Aminolevulinic Acid"
    },
    {
      "QualifierName": [
        "adverse effects",
        "methods"
      ],
      "DescriptorName": "Combined Modality Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cryotherapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Progression"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology",
        "pathology",
        "therapy"
      ],
      "DescriptorName": "Keratosis, Actinic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "adverse effects",
        "methods"
      ],
      "DescriptorName": "Photochemotherapy"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Photosensitizing Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recurrence"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Secondary Prevention"
    },
    {
      "QualifierName": [
        "pathology",
        "prevention & control"
      ],
      "DescriptorName": "Skin Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}